Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prime Medicine, Inc.

4.04
+0.30008.02%
Post-market: 4.320.2800+6.93%19:57 EDT
Volume:4.74M
Turnover:18.40M
Market Cap:529.33M
PE:-2.50
High:4.07
Open:3.51
Low:3.51
Close:3.74
Loading ...

Prime Medicine price target raised to $16 from $15 at Chardan

TIPRANKS
·
20 Mar

Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating

MT Newswires Live
·
20 Mar

Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential

TIPRANKS
·
19 Mar

Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar

Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating

TIPRANKS
·
19 Mar

Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating

MT Newswires Live
·
19 Mar

BRIEF-Prime Medicine Unveils Program For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)

Reuters
·
18 Mar

Prime Medicine Price Target Maintained With a $10.00/Share by Citizens Capital Markets

Dow Jones
·
04 Mar

Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Mar

Prime Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
03 Mar

TD Cowen Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)

TIPRANKS
·
28 Feb

Prime Medicine reports FY24 EPS ($1.65) vs ($2.18) last year

TIPRANKS
·
28 Feb

Prime Medicine FY 2024 GAAP EPS $(1.65) Beats $(1.66) Estimate, Sales $2.983M Beats $929.100K Estimate

Benzinga
·
28 Feb

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire
·
28 Feb

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
24 Feb